Zymeworks Inc. (ZYME)

Market Cap	839.34M
Revenue (ttm)	93.38M
Net Income (ttm)	-113.68M
Shares Out	69.68M
EPS (ttm)	-1.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	533,312
Open	11.61
Previous Close	11.31
Day's Range	11.34 - 12.20
52-Week Range	8.21 - 17.70
Beta	1.24
Analysts	Buy
Price Target	19.50 (+61.89%)
Earnings Date	May 8, 2025

About ZYME

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprisin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 28, 2017
• Employees: 286
• Stock Exchange: NASDAQ
• Ticker Symbol: ZYME
• Website: https://www.zymeworks.com

Financial Performance

In 2024, Zymeworks's revenue was $76.30 million, an increase of 0.38% compared to the previous year's $76.01 million. Losses were -$122.70 million, 3.39% more than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for ZYME stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 61.89% from the latest price.

Price Target

$19.5

(61.89% upside)

Analyst Consensus: Buy